Wierzbicki A S
Department of Chemical Pathology, St Thomas' Hospital, London, UK.
Int J Clin Pract. 1997 Sep;51(6):378-83.
Hyperlipidaemia is acknowledged as the major risk factor for coronary heart disease and atheroma progression. This review considers the strategies that should be followed to reduce overall cardiovascular risk in patients with hyperlipidaemia and deals with the identification and management of treating both polygenic and monogenic lipid disorders in the presence or absence of overt cardiovascular disease.
高脂血症被认为是冠心病和动脉粥样硬化进展的主要危险因素。本综述探讨了高脂血症患者降低总体心血管风险应遵循的策略，并涉及在存在或不存在明显心血管疾病的情况下，识别和管理多基因和单基因脂质紊乱的治疗方法。
